PainRelief.com Interview with:
Professor Messoud Ashina, MD, PhD, DMSc
Department of Neurology and Danish Headache Center
Glostrup Hospital
University of Copenhagen, Glostrup
Copenhagen, Denmark

PainRelief.com: What is the background for this study?

Background and Main Findings: Current migraine treatments targeting CGRP aren’t fully effective for everyone. PACAP is another key molecule implicated in migraine and can trigger migraine attacks. Lu AG09222, an antibody that blocks PACAP, has shown promise in reducing migraine days in a phase 2a trial.

Effects Duration: 4 weeks.

Last Updated on September 4, 2024 by PainRelief.com